Biotech Finance, Jobs, and Policy
Kilder
- Endpoints: Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins
- Labiotech: Genomes to bioreactors: Saudi Arabia’s gene editing oncology push
- STAT: Opinion: STAT+: A bill is supposed to protect U.S. biotech from Chinese competition. But there’s a loophole
- Raps: Recon: FDA weighs new deputy commissioner posts; Trump set to reveal more MFN drug pricing deals - RAPS
- Ua: US Congress considers BINSA biotechnology bill - UA.NEWS
- BioPharma Dive: Michael Polansky has a new, skin-focused biotech. Don’t call it a drug company.
- BioSpace: Nearly 1/4 dealing with long-term unemployment call it quits on biopharma job searches
- Raps: Recon: FDA weighs new deputy commissioner posts; Trump set to reveal more MFN drug pricing deals - RAPS
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.